Wyeth’s Pipeline Star Bapineuzumab Looks More Long Shot Than Sure Bet
This article was originally published in The Pink Sheet Daily
Executive Summary
Following the release of lackluster Phase II efficacy data on bapineuzumab in Alzheimer’s disease patients, talk of Wyeth as a takeover target resurfaces.
You may also be interested in...
Insider Trading Spectrum: From Small-Scale Buddies To “Most Lucrative Inside Tip Of All Time”
SEC was able to trace trading patterns and relationships between former high school friends back to employees at Celgene and Sanofi; SEC also filed a complaint against a former hedge fund manager who made a record $276 million profit trading on insider information about Alzheimer’s disease drug bapineuzumab.
SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports
At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.
SEC Investigates Elan Over Disclosures of Clinical Trial Data and Side Effect Reports
At issue: July 2008 reports of PML cases linked to Tysabri and key trial data for its Alzheimer's medication; Wyeth also gets a subpoena.